BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sciascia S, Cuadrado MJ, Khamashta M, Roccatello D. Renal involvement in antiphospholipid syndrome. Nat Rev Nephrol. 2014;10:279-289. [PMID: 24642799 DOI: 10.1038/nrneph.2014.38] [Cited by in Crossref: 58] [Cited by in F6Publishing: 49] [Article Influence: 7.3] [Reference Citation Analysis]
Number Citing Articles
1 Klumb EM, Silva CAA, Lanna CCD, Sato EI, Borba EF, Brenol JCT, Albuquerque EMDND, Monticielo OA, Costallat LTL, Latorre LC, Sauma MDFLDC, Bonfá ESDDO, Ribeiro FM. Consenso da Sociedade Brasileira de Reumatologia para o diagnóstico, manejo e tratamento da nefrite lúpica. Revista Brasileira de Reumatologia 2015;55:1-21. [DOI: 10.1016/j.rbr.2014.09.008] [Cited by in Crossref: 32] [Cited by in F6Publishing: 20] [Article Influence: 4.6] [Reference Citation Analysis]
2 Sciascia S, Radin M, Yazdany J, Tektonidou M, Cecchi I, Roccatello D, Dall’era M. Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence. Rheumatol Int 2017;37:1249-55. [DOI: 10.1007/s00296-017-3686-5] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 7.4] [Reference Citation Analysis]
3 Broder A, Mowrey WB, Kim M, Murakhovskaya I, Billett H, Neugarten J, Costenbader KH, Putterman C. Association between antiphospholipid antibodies and all-cause mortality among end-stage renal disease patients with and without SLE: a retrospective cohort study. Rheumatology (Oxford) 2016;55:817-25. [PMID: 26705328 DOI: 10.1093/rheumatology/kev423] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
4 Pengo V, Denas G. Diagnostics and treatment of thrombotic antiphospholipid syndrome (APS): A personal perspective. Thromb Res 2018;169:35-40. [PMID: 30007134 DOI: 10.1016/j.thromres.2018.07.011] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
5 Berger BE. Atypical hemolytic uremic syndrome: a syndrome in need of clarity. Clin Kidney J 2019;12:338-47. [PMID: 31198222 DOI: 10.1093/ckj/sfy066] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
6 Cochery-Nouvellon É, Mercier É, Bouvier S, Balducchi JP, Quéré I, Perez-Martin A, Mousty E, Letouzey V, Gris JC. Obstetric antiphospholipid syndrome: early variations of angiogenic factors are associated with adverse outcomes. Haematologica 2017;102:835-42. [PMID: 28126966 DOI: 10.3324/haematol.2016.155184] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
7 Ponticelli C, Doria A, Moroni G. Renal disorders in rheumatologic diseases: the spectrum is changing (Part 1: connective tissue diseases). J Nephrol 2021;34:1069-80. [PMID: 32529559 DOI: 10.1007/s40620-020-00772-7] [Reference Citation Analysis]
8 Salvadori M, Tsalouchos A. Therapeutic apheresis in kidney transplantation: An updated review. World J Transplant 2019; 9(6): 103-122 [PMID: 31750088 DOI: 10.5500/wjt.v9.i6.103] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
9 Turrent-Carriles A, Herrera-Félix JP, Amigo MC. Renal Involvement in Antiphospholipid Syndrome. Front Immunol 2018;9:1008. [PMID: 29867982 DOI: 10.3389/fimmu.2018.01008] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.8] [Reference Citation Analysis]
10 Anders HJ, Saxena R, Zhao MH, Parodis I, Salmon JE, Mohan C. Lupus nephritis. Nat Rev Dis Primers 2020;6:7. [PMID: 31974366 DOI: 10.1038/s41572-019-0141-9] [Cited by in Crossref: 57] [Cited by in F6Publishing: 50] [Article Influence: 28.5] [Reference Citation Analysis]
11 Sciascia S, Radin M, Cecchi I, Fenoglio R, De Marchi A, Besso L, Baldovino S, Rossi D, Miraglia P, Rubini E, Roccatello D. Anti-beta-2-glycoprotein I domain 1 identifies antiphospholipid antibodies-related injuries in patients with concomitant lupus nephritis. J Nephrol 2020;33:757-62. [PMID: 31974856 DOI: 10.1007/s40620-019-00698-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Ahn SS, Jung SM, Yoo J, Lee SW, Song JJ, Park YB. Clinical characteristics of patients with systemic lupus erythematosus showing a false-positive result of syphilis screening. Rheumatol Int 2019;39:1859-66. [PMID: 31468123 DOI: 10.1007/s00296-019-04435-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
13 Parajuli S, Lockridge JB, Langewisch ED, Norman DJ, Kujovich JL. Hypercoagulability in Kidney Transplant Recipients. Transplantation. 2016;100:719-726. [PMID: 26413991 DOI: 10.1097/tp.0000000000000887] [Cited by in Crossref: 24] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
14 Sciascia S, Yazdany J, Dall'Era M, Fenoglio R, Radin M, Aggarwal I, Cuadrado MJ, Schreiber K, Barreca A, Papotti M, Roccatello D. Anticoagulation in patients with concomitant lupus nephritis and thrombotic microangiopathy: a multicentre cohort study. Ann Rheum Dis 2019;78:1004-6. [PMID: 30552172 DOI: 10.1136/annrheumdis-2018-214559] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
15 Sjöwall C, Bentow C, Aure MA, Mahler M. Two-Parametric Immunological Score Development for Assessing Renal Involvement and Disease Activity in Systemic Lupus Erythematosus. J Immunol Res 2018;2018:1294680. [PMID: 30246032 DOI: 10.1155/2018/1294680] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
16 Negrini S, Pappalardo F, Murdaca G, Indiveri F, Puppo F. The antiphospholipid syndrome: from pathophysiology to treatment. Clin Exp Med 2017;17:257-67. [PMID: 27334977 DOI: 10.1007/s10238-016-0430-5] [Cited by in Crossref: 47] [Cited by in F6Publishing: 28] [Article Influence: 7.8] [Reference Citation Analysis]
17 Merashli M, Noureldine MHA, Uthman I, Khamashta M. Antiphospholipid syndrome: an update. Eur J Clin Invest 2015;45:653-62. [DOI: 10.1111/eci.12449] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 3.9] [Reference Citation Analysis]
18 Torres-jimenez A, Ramirez-nova V, Cespedes-cruz AI, Sanchez-jara B, Velazquez-cruz A, Bekker-méndez VC, Guerra-castillo FX. Primary antiphospholipid syndrome in pediatrics: beyond thrombosis. Report of 32 cases and review of the evidence. Pediatr Rheumatol 2022;20. [DOI: 10.1186/s12969-022-00673-y] [Reference Citation Analysis]
19 Corban MT, Duarte-Garcia A, McBane RD, Matteson EL, Lerman LO, Lerman A. Antiphospholipid Syndrome: Role of Vascular Endothelial Cells and Implications for Risk Stratification and Targeted Therapeutics. J Am Coll Cardiol. 2017;69:2317-2330. [PMID: 28473138 DOI: 10.1016/j.jacc.2017.02.058] [Cited by in Crossref: 55] [Cited by in F6Publishing: 46] [Article Influence: 11.0] [Reference Citation Analysis]
20 Mancardi D, Arrigo E, Cozzi M, Cecchi I, Radin M, Fenoglio R, Roccatello D, Sciascia S. Endothelial dysfunction and cardiovascular risk in lupus nephritis: New roles for old players? Eur J Clin Invest 2021;51:e13441. [PMID: 33128260 DOI: 10.1111/eci.13441] [Reference Citation Analysis]
21 Sciascia S, Baldovino S, Schreiber K, Solfietti L, Roccatello D. Antiphospholipid Syndrome and the Kidney. Semin Nephrol 2015;35:478-86. [PMID: 26573550 DOI: 10.1016/j.semnephrol.2015.08.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
22 Ghassemi A, Bharadia J, Liu A. Acute renal infarction, transient ischemic attack, and biventricular thrombi secondary to substance use disorder: A case report. Clin Case Rep 2019;7:861-4. [PMID: 31110704 DOI: 10.1002/ccr3.2101] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
23 Barrera-Vargas A, Rosado-Canto R, Merayo-Chalico J, Arreola-Guerra JM, Mejía-Vilet JM, Correa-Rotter R, Gómez-Martín D, Alcocer-Varela J. Renal Thrombotic Microangiopathy in Proliferative Lupus Nephritis: Risk Factors and Clinical Outcomes: A Case-Control Study. J Clin Rheumatol 2016;22:235-40. [PMID: 27464767 DOI: 10.1097/RHU.0000000000000425] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 3.2] [Reference Citation Analysis]
24 Linnemann B. Antiphospholipid syndrome – an update. Vasa 2018;47:451-64. [DOI: 10.1024/0301-1526/a000723] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 9.0] [Reference Citation Analysis]
25 Arneth B. Defects in ubiquitination and NETosis and their associations with human diseases. Pathology 2021;53:439-45. [PMID: 33518384 DOI: 10.1016/j.pathol.2020.10.014] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Sciascia S, Amigo MC, Roccatello D, Khamashta M. Diagnosing antiphospholipid syndrome: 'extra-criteria' manifestations and technical advances. Nat Rev Rheumatol 2017;13:548-60. [PMID: 28769114 DOI: 10.1038/nrrheum.2017.124] [Cited by in Crossref: 71] [Cited by in F6Publishing: 60] [Article Influence: 14.2] [Reference Citation Analysis]
27 Nasri H, Ahmadi A, Baradaran A, Momeni A, Nasri P, Mardani S, Rafieian-Kopaei M, Mubarak M. Clinicopathological correlations in lupus nephritis; a single center experience. J Nephropathol 2014;3:115-20. [PMID: 25093160 DOI: 10.12860/jnp.2014.22] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
28 Marcantoni C, Emmanuele C, Scolari F. Renal involvement in primary antiphospholipid syndrome. J Nephrol 2016;29:507-15. [PMID: 27198137 DOI: 10.1007/s40620-016-0317-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
29 Abeysekera RA, Wazil AW, Nanayakkara N, Ratnatunga NV, Fernando KM, Thinnarachchi J. Primary antiphospholipid syndrome presenting as antiphospholipid syndrome nephropathy: a case report. J Med Case Rep 2015;9:28. [PMID: 25630456 DOI: 10.1186/1752-1947-9-28] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
30 Belizna C, Stojanovich L, Cohen-Tervaert JW, Fassot C, Henrion D, Loufrani L, Nagy G, Muchardt C, Hasan M, Ungeheuer MN, Arnaud L, Alijotas-Reig J, Esteve-Valverde E, Nicoletti F, Saulnier P, Godon A, Reynier P, Chrétien JM, Damian L, Omarjee L, Mahé G, Pistorius MA, Meroni PL, Devreese K. Primary antiphospholipid syndrome and antiphospholipid syndrome associated to systemic lupus: Are they different entities? Autoimmun Rev 2018;17:739-45. [PMID: 29885541 DOI: 10.1016/j.autrev.2018.01.027] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
31 Rosa RF, Ugolini-lopes MR, Zeinad-valim AK, D’amico E, Andrade D. Difficult Clinical Situations in the Antiphospholipid Syndrome. Curr Rheumatol Rep 2015;17. [DOI: 10.1007/s11926-015-0502-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 2.1] [Reference Citation Analysis]
32 Scheen M, Adedjouma A, Esteve E, Buob D, Abisror N, Planche V, Fain O, Boffa JJ, De Seigneux S, Mekinian A, Haidar F. Kidney disease in antiphospholipid antibody syndrome: Risk factors, pathophysiology and management. Autoimmun Rev 2022;:103072. [PMID: 35217200 DOI: 10.1016/j.autrev.2022.103072] [Reference Citation Analysis]
33 Gauthier M, Canoui-poitrine F, Guéry E, Desvaux D, Hue S, Canaud G, Stehle T, Lang P, Kofman T, Grimbert P, Matignon M. Anticardiolipin antibodies and 12-month graft function in kidney transplant recipients: a prognosis cohort survey. Nephrology Dialysis Transplantation 2018;33:709-16. [DOI: 10.1093/ndt/gfx353] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
34 Martínez-Flores JA, Serrano M, Morales JM, Serrano A. Antiphospholipid Syndrome and Kidney Involvement: New Insights. Antibodies (Basel) 2016;5:E17. [PMID: 31557998 DOI: 10.3390/antib5030017] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
35 Sofue T, Hayashida Y, Hara T, Kawakami K, Ueda N, Kushida Y, Inui M, Dobashi H, Kakehi Y, Kohno M. Plasmapheresis in a patient with antiphospholipid syndrome before living-donor kidney transplantation: a case report. BMC Nephrol. 2014;15:167. [PMID: 25319344 DOI: 10.1186/1471-2369-15-167] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
36 Espinosa G, Cervera R. Current treatment of antiphospholipid syndrome: lights and shadows. Nat Rev Rheumatol 2015;11:586-96. [PMID: 26122952 DOI: 10.1038/nrrheum.2015.88] [Cited by in Crossref: 79] [Cited by in F6Publishing: 60] [Article Influence: 11.3] [Reference Citation Analysis]
37 Ugolini-lopes MR, Criado PR, Parsi K, Kucukkaya RD, Amigo M, Tektonidou MG, Andrade D. Treatment of Non-criteria Manifestations in Antiphospholipid Syndrome. In: Erkan D, Lockshin MD, editors. Antiphospholipid Syndrome. Cham: Springer International Publishing; 2017. pp. 247-66. [DOI: 10.1007/978-3-319-55442-6_13] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
38 Gracia-Tello B, Isenberg D. Kidney disease in primary anti-phospholipid antibody syndrome. Rheumatology (Oxford) 2017;56:1069-80. [PMID: 27550302 DOI: 10.1093/rheumatology/kew307] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
39 Dema B, Charles N. Autoantibodies in SLE: Specificities, Isotypes and Receptors. Antibodies (Basel) 2016;5:E2. [PMID: 31557984 DOI: 10.3390/antib5010002] [Cited by in Crossref: 35] [Cited by in F6Publishing: 25] [Article Influence: 5.8] [Reference Citation Analysis]
40 Morales JM, Serrano M, Martinez-flores JA, Perez D, Serrano A. Antiphospholipid Syndrome and Renal Allograft Thrombosis. Transplantation 2019;103:481-6. [DOI: 10.1097/tp.0000000000002510] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
41 Gupta S, Kaplan MJ. The role of neutrophils and NETosis in autoimmune and renal diseases. Nat Rev Nephrol 2016;12:402-13. [PMID: 27241241 DOI: 10.1038/nrneph.2016.71] [Cited by in Crossref: 195] [Cited by in F6Publishing: 189] [Article Influence: 32.5] [Reference Citation Analysis]
42 Lee E, Yeo MK, You SK, Kim YK, Ryu S, Lee JM. An Unusual Pediatric Case of Seronegative Systemic Lupus Erythematosus Presented With Acute Abdominal Pain and Gross Hematuria. Pediatr Emerg Care 2021;37:e55-7. [PMID: 29794960 DOI: 10.1097/PEC.0000000000001527] [Reference Citation Analysis]
43 Nasonov EL, Reshetnyak TM, Alekberova ZS. [Thrombotic microangiopathy in rheumatology: a link between thrombosis and autoimmunity]. Ter Arkh 2020;92:4-14. [PMID: 32598770 DOI: 10.26442/00403660.2020.05.000697] [Cited by in Crossref: 5] [Article Influence: 2.5] [Reference Citation Analysis]
44 Talari K, Anandh U, Patrick A. Lupus Nephritis with Coexistent Antiphospholipid Antibodies Associated Nephropathy: A Case Report and Literature Review. Indian J Nephrol 2018;28:164-6. [PMID: 29861569 DOI: 10.4103/ijn.IJN_204_16] [Reference Citation Analysis]
45 Toffoli B, Gilardi F, Winkler C, Soderberg M, Kowalczuk L, Arsenijevic Y, Bamberg K, Bonny O, Desvergne B. Nephropathy in Pparg-null mice highlights PPARγ systemic activities in metabolism and in the immune system. PLoS One 2017;12:e0171474. [PMID: 28182703 DOI: 10.1371/journal.pone.0171474] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
46 Ichikawa K, Konta T, Sato H, Ueda Y, Yokoyama H. The clinical and pathological characteristics of nephropathies in connective tissue diseases in the Japan Renal Biopsy Registry (J-RBR). Clin Exp Nephrol 2017;21:1024-9. [DOI: 10.1007/s10157-017-1398-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
47 Emmi G, Silvestri E, Squatrito D, Ciucciarelli L, Cameli AM, Denas G, D'Elios MM, Pengo V, Emmi L, Prisco D. An approach to differential diagnosis of antiphospholipid antibody syndrome and related conditions. ScientificWorldJournal 2014;2014:341342. [PMID: 25374937 DOI: 10.1155/2014/341342] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
48 Berger BE. The Alternative Pathway of Complement and the Evolving Clinical-Pathophysiological Spectrum of Atypical Hemolytic Uremic Syndrome. Am J Med Sci 2016;352:177-90. [PMID: 27524217 DOI: 10.1016/j.amjms.2016.05.003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
49 Pan Q, Guo F, Huang Y, Li A, Chen S, Chen J, Liu HF, Pan Q. Gut Microbiota Dysbiosis in Systemic Lupus Erythematosus: Novel Insights into Mechanisms and Promising Therapeutic Strategies. Front Immunol 2021;12:799788. [PMID: 34925385 DOI: 10.3389/fimmu.2021.799788] [Reference Citation Analysis]
50 Kello N, Khoury LE, Marder G, Furie R, Zapantis E, Horowitz DL. Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: Case series and review of literature. Semin Arthritis Rheum 2019;49:74-83. [PMID: 30598332 DOI: 10.1016/j.semarthrit.2018.11.005] [Cited by in Crossref: 47] [Cited by in F6Publishing: 36] [Article Influence: 11.8] [Reference Citation Analysis]
51 Roccatello D, Sciascia S, Rossi D, Naretto C, Bazzan M, Solfietti L, Sandrone M, Radin M, Baldovino S, Menegatti E. Safety of outpatient percutaneous native renal biopsy in systemic autoimmune diseases: results from a monocentric cohort. Lupus 2018;27:1393-4. [PMID: 29325491 DOI: 10.1177/0961203317751645] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
52 Furmańczyk-Zawiska A, Bączkowska T, Dęborska-Materkowska D, Nazarewski S, Kosieradzki M, Durlik M. Effect of Thrombophilic Factors on Renal Graft Function: A Single-Center Experience. Transplant Proc 2018;50:1715-9. [PMID: 30056888 DOI: 10.1016/j.transproceed.2018.02.096] [Reference Citation Analysis]
53 Yap DYH, Thong KM, Yung S, Tang C, Ma BMY, Chan TM. Antiphospholipid antibodies in patients with lupus nephritis: clinical correlations and associations with long-term outcomes. Lupus 2019;28:1460-7. [PMID: 31594451 DOI: 10.1177/0961203319879990] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
54 Horita S, Zoshima T, Hara S, Koichi M, Hirayama S, Suzuki K, Nakashima A, Kawano M. Antiphospholipid antibody syndrome-associated renal thrombotic microangiopathy improved not with rivaroxaban but with warfarin in a systemic lupus erythematosus patient without lupus nephritis. CEN Case Rep 2021;10:409-13. [PMID: 33595828 DOI: 10.1007/s13730-021-00581-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]